ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE

Pamiparib, an investigational, selective PARP1/2 inhibitor that has demonstrated potent PARP trapping and ability to cross the blood-brain barrier, showed synergistic cytotoxicity with TMZ preclinically. We report updated safety and antitumor effects from a phase 1b/2 study of pamiparib + RT and/or...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Piotrowski, Anna, Puduvalli, Vinay, Wen, Patrick, Campian, Jian, Colman, Howard, Pearlman, Michael, Butowski, Nicholas, Battiste, James, Glass, Jon, Cloughesy, Timothy, Schiff, David, van den Bent, Martin, Walbert, Tobias, Ahluwalia, Manmeet, Badruddoja, Michael, Kalra, Amandeep, Aregawi, Dawit, Weller, Michael, Ramakrishnan, Vanitha, Zhang, Kathy, Wood, Katie, Mellinghoff, Ingo, Shih, Kent
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Adult Clinical Trials - Non-Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847934/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.081
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars